Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Combined With Ivonescimab in Advanced NSCLC
NCT07412262Phase 2Recruiting
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Aug 2026
- Primary completion
- Mar 2028
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tucidinostat, ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Started Aug 2026; status: recruiting.
02
Drugs
tucidinostativonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07412262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07412262.